

Special Issue

Bacterial Vaccine: Mucosal Immunity and Implications

Message from the Guest Editors

Although numerous effective mucosal vaccines are in use, the use of these vaccines has not yet been translated into licensed mucosal vaccines and this is due to its solely live attenuated and inactivated whole-cell preparations. Therefore, this Special Issue in *Vaccines* reflects the research interest of scientific communities involved in studying therapeutics or prophylactic interventions against bacterial pathogens, infecting via mucosal barriers. Additionally, the development of mucosal bacterial vaccines will offer a potential fortification at the mucosal site of entry. Publication of scientific studies or potential research work focusing on vaccine development, host-pathogen interaction, establishment of protection innate and adaptive immune factors, and their mechanism of cross-talk will be considered equally.

Guest Editors

Dr. Amit K. Singh

Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA

Dr. Raj Kumar

Department of Physiology, The University of Tennessee Health Science Center, Memphis, TN 38163, USA

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/132383

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).